Conclusion: These data suggest that enhanced glycolysis by EGFR mutation is required for maintaining EGFR levels through inhibition of JNK-induced autophagy, providing a promising rational for exploring JNK activators for patient bearing EGFR-mutation NSCLC. The gene discussed is MAPK8; the disease is non-small cell lung carcinoma.